The Patent Finder

Xuanzhu Pharma Co., Ltd.

9 patents currently held · Updated Nov 19, 2026
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

0
Ending by 2030
Aug 2031
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Tyrosine kinase inhibitor and uses thereof (US 10,300,058) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 1 fee due May 10, 2027
    The maintenance fee for Substituted pyrido[2,3-c]pyridazin-4(1H)-ones as tumor necrosis factor alpha and phosphodiesterase 4 inhibitors (US 9,181,244) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
  • 1 fee due Jun 17, 2027
    The maintenance fee for Quinazoline derivatives substituted by aniline, preparation method and use thereof (US 10,507,209) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
  • 1 fee due Sep 15, 2027
    The maintenance fee for Three-ring PI3K and/or mTOR inhibitor (US 9,284,315) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
  • 2 fees due Oct 19 to 28, 2027 · next Oct 19

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,507,209Quinazoline derivatives substituted by aniline, preparation method and use thereof
In force
 · USPTO record
In forceUSPTO record
US 9,315,513Benzimidazole derivatives and their pharmaceutical compositions and uses
In force
 · USPTO record
In forceUSPTO record
US 9,284,315Three-ring PI3K and/or mTOR inhibitor
In force
 · USPTO record
In forceUSPTO record
US 9,365,572PI3K and/or mTOR inhibitor
In force
 · USPTO record
In forceUSPTO record
US 9,181,244Substituted pyrido[2,3-c]pyridazin-4(1H)-ones as tumor necrosis factor alpha and phosphodiesterase 4 inhibitors
In force
 · USPTO record
In forceUSPTO record
US 10,300,058Tyrosine kinase inhibitor and uses thereof
In force
 · USPTO record
In forceUSPTO record
US 10,167,283ß-Lactamase Inhibitors and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,633,364Crystals of quinazoline derivative and preparation method therefor
In force
 · USPTO record
In forceUSPTO record
US 10,689,359Crystals of quinazoline derivative and preparation method therefor
In force
 · USPTO record
In forceUSPTO record
Also on record, not counted in the 9: 14 patents in force now held by others · 10 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited